Schrodinger (SDGR)
(Delayed Data from NSDQ)
$21.37 USD
-0.42 (-1.93%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $21.36 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.37 USD
-0.42 (-1.93%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $21.36 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Zacks News
4 Mid-Cap Stocks to Buy Ahead of Earnings Results This week
by Nalak Das
The four mid-cap stocks discussed here are slated to release earnings results this week. These are CACI, SDGR, AVT and GRWG.
National Vision (EYE) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
National Vision (EYE) is expected to report sequentially better results for the second quarter on gradual reopening of stores and return toward more normal operations.
Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Schrodinger, Inc. (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Harrow Health (HROW) in Q2 Earnings?
by Zacks Equity Research
Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.
Schrodinger (SDGR) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Schrodinger (SDGR) has been struggling lately, but the selling pressure may be coming to an end soon.
Schrodinger, Inc. (SDGR) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 100.00% and 10.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger (SDGR) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Schrodinger's (SDGR) first-quarter results are likely to reflect benefits from collaborations.
Schrodinger, Inc. (SDGR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Nov 24, 2020
by Zacks Equity Research
Companies in the news are: SDGR, IDEX, DPW, RESI
Schrodinger (SDGR) Jumps: Stock Rises 8.5%
by Zacks Equity Research
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Schrodinger (SDGR) Catches Eye: Stock Jumps 9.3%
by Zacks Equity Research
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Medical Products Stock Earnings on Aug 10: CGC, SDGR & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Medical Products' Earnings Roster for May 13: SDC, STE & More
by Urmimala Biswas
Many medical product companies register strong earnings growth in Q1, riding on huge market adoption of their COVID-19-related support products and growing demand for non-elective procedures.